Patents by Inventor James Fandl

James Fandl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210340564
    Abstract: The invention provides a new expression system comprising a mammalian selectable marker that promotes desirable post-translational modifications of glycoproteins. In particular, the invention includes methods and compositions for optimal recombinant protein expression in mammalian cells by employing a selection marker system based on GPT genes of mammalian origin. The invention includes methods that facilitate selectivity and enhanced expression copies as well as protein yield of recombinant proteins in mammalian cells, and methods of using GPT expression systems.
    Type: Application
    Filed: July 2, 2021
    Publication date: November 4, 2021
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Dipali Deshpande, Darya Burakov, Gang Chen, James Fandl
  • Patent number: 11085053
    Abstract: The invention provides a new expression system comprising a mammalian selectable marker that promotes desirable post-translational modifications of glycoproteins. In particular, the invention includes methods and compositions for optimal recombinant protein expression in mammalian cells by employing a selection marker system based on GPT genes of mammalian origin. The invention includes methods that facilitate selectivity and enhanced expression copies as well as protein yield of recombinant proteins in mammalian cells, and methods of using GPT expression systems.
    Type: Grant
    Filed: September 10, 2019
    Date of Patent: August 10, 2021
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Dipali Deshpande, Darya Burakov, Gang Chen, James Fandl
  • Publication number: 20210009714
    Abstract: Recombinant cell surface capture proteins and detection molecules that are useful for isolating and detecting cells that produce a secreted heterodimeric protein of interest (POI) that has an immunoglobulin CH3 domain and/or substituted CH3 domain are provided. Recombinant cell surface capture proteins and detection molecules that isolate and detect bispecific antibodies are also provided. The invention also provides recombinant antigen-binding proteins that are capable of recognizing and binding to proteins of interest that contain a CH3 domain and/or a modified CH3 domain, such as a CH3 domain with or without amino acid substitutions at H95 and Y96 (IMGT).
    Type: Application
    Filed: September 18, 2020
    Publication date: January 14, 2021
    Inventors: Dipali Deshpande, Gang Chen, Darya Burakov, James Fandl, Thomas Aldrich, Vishal Kamat
  • Publication number: 20200063159
    Abstract: The invention provides a new expression system comprising a mammalian selectable marker that promotes desirable post-translational modifications of glycoproteins. In particular, the invention includes methods and compositions for optimal recombinant protein expression in mammalian cells by employing a selection marker system based on GPT genes of mammalian origin. The invention includes methods that facilitate selectivity and enhanced expression copies as well as protein yield of recombinant proteins in mammalian cells, and methods of using GPT expression systems.
    Type: Application
    Filed: September 10, 2019
    Publication date: February 27, 2020
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Dipali Deshpande, Darya Burakov, Gang Chen, James Fandl
  • Patent number: 10457959
    Abstract: The invention provides a new expression system comprising a mammalian selectable marker that promotes desirable post-translational modifications of glycoproteins. In particular, the invention includes methods and compositions for optimal recombinant protein expression in mammalian cells by employing a selection marker system based on GPT genes of mammalian origin. The invention includes methods that facilitate selectivity and enhanced expression copies as well as protein yield of recombinant proteins in mammalian cells, and methods of using GPT expression systems.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: October 29, 2019
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Dipali Deshpande, Darya Burakov, Gang Chen, James Fandl
  • Publication number: 20180118852
    Abstract: Recombinant cell surface capture proteins and detection molecules that are useful for isolating and detecting cells that produce a secreted heterodimeric protein of interest (POI) that has an immunoglobulin CH3 domain and/or substituted CH3 domain are provided. Recombinant cell surface capture proteins and detection molecules that isolate and detect bispecific antibodies are also provided. The invention also provides recombinant antigen-binding proteins that are capable of recognizing and binding to proteins of interest that contain a CH3 domain and/or a modified CH3 domain, such as a CH3 domain with or without amino acid substitutions at H95 and Y96 (IMGT).
    Type: Application
    Filed: September 11, 2017
    Publication date: May 3, 2018
    Inventors: Dipali Deshpande, Gang Chen, Darya Burakov, James Fandl, Thomas Aldrich, Vishal Kamat
  • Publication number: 20170335341
    Abstract: The invention provides a new expression system comprising a mammalian selectable marker that promotes desirable post-translational modifications of glycoproteins. In particular, the invention includes methods and compositions for optimal recombinant protein expression in mammalian cells by employing a selection marker system based on GPT genes of mammalian origin. The invention includes methods that facilitate selectivity and enhanced expression copies as well as protein yield of recombinant proteins in mammalian cells, and methods of using GPT expression systems.
    Type: Application
    Filed: July 31, 2017
    Publication date: November 23, 2017
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Dipali Deshpande, Darya Burakov, Gang Chen, James Fandl
  • Patent number: 9758592
    Abstract: Recombinant cell surface capture proteins and detection molecules that are useful for isolating and detecting cells that produce a secreted heterodimeric protein of interest (POI) that has an immunoglobulin CH3 domain and/or substituted CH3 domain are provided. Recombinant cell surface capture proteins and detection molecules that isolate and detect bispecific antibodies are also provided. The invention also provides recombinant antigen-binding proteins that are capable of recognizing and binding to proteins of interest that contain a CH3 domain and/or a modified CH3 domain, such as a CH3 domain with or without amino acid substitutions at H95 and Y96 (IMGT).
    Type: Grant
    Filed: November 14, 2013
    Date of Patent: September 12, 2017
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Dipali Deshpande, Gang Chen, Darya Burakov, James Fandl, Thomas Aldrich, Vishal Kamat
  • Patent number: 9732357
    Abstract: The invention provides a new expression system comprising a mammalian selectable marker that promotes desirable post-translational modifications of glycoproteins. In particular, the invention includes methods and compositions for optimal recombinant protein expression in mammalian cells by employing a selection marker system based on GPT genes of mammalian origin. The invention includes methods that facilitate selectivity and enhanced expression copies as well as protein yield of recombinant proteins in mammalian cells, and methods of using GPT expression systems.
    Type: Grant
    Filed: August 19, 2015
    Date of Patent: August 15, 2017
    Assignee: REGENERON PHARMACEUTICALS
    Inventors: Dipali Deshpande, Darya Burakov, Gang Chen, James Fandl
  • Publication number: 20160053280
    Abstract: The invention provides a new expression system comprising a mammalian selectable marker that promotes desirable post-translational modifications of glycoproteins. In particular, the invention includes methods and compositions for optimal recombinant protein expression in mammalian cells by employing a selection marker system based on GPT genes of mammalian origin. The invention includes methods that facilitate selectivity and enhanced expression copies as well as protein yield of recombinant proteins in mammalian cells, and methods of using GPT expression systems.
    Type: Application
    Filed: August 19, 2015
    Publication date: February 25, 2016
    Inventors: Dipali DESHPANDE, Darya BURAKOV, Gang CHEN, James FANDL
  • Publication number: 20140134719
    Abstract: Recombinant cell surface capture proteins and detection molecules that are useful for isolating and detecting cells that produce a secreted heterodimeric protein of interest (POI) that has an immunoglobulin CH3 domain and/or substituted CH3 domain are provided. Recombinant cell surface capture proteins and detection molecules that isolate and detect bispecific antibodies are also provided. The invention also provides recombinant antigen-binding proteins that are capable of recognizing and binding to proteins of interest that contain a CH3 domain and/or a modified CH3 domain, such as a CH3 domain with or without amino acid substitutions at H95 and Y96 (IMGT).
    Type: Application
    Filed: November 14, 2013
    Publication date: May 15, 2014
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: DIPALI DESHPANDE, GANG CHEN, DARYA BURAKOV, JAMES FANDL, THOMAS ALDRICH, VISHAL KAMAT
  • Publication number: 20070280945
    Abstract: A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a KD of about 500 pM or less and blocks IL-6 activity with an IC50 of 200 pM or less. In preferred embodiments, the antibody the antibody or antigen-binding fragment binds hIL-6R with an affinity at least 2-fold higher relative to its binding monkey IL-6R.
    Type: Application
    Filed: June 1, 2007
    Publication date: December 6, 2007
    Inventors: Sean Stevens, Tammy Huang, Joel Martin, Jeanette Fairhurst, Ashique Rafique, Eric Smith, Kevin Pobursky, Nicholas Papadopoulos, James Fandl, Gang Chen, Margaret Karow
  • Publication number: 20060234311
    Abstract: A method of detecting and isolating cells that produce any secreted protein of interest (POI), comprising: a) constructing a cell line transiently or stably expressing a cell surface capture molecule, which binds the POI, by transfecting the cell line with a nucleic acid that encodes such cell surface capture molecule; b) transfecting said cell simultaneously or subsequently with a second nucleic acid that encodes a POI wherein such POI is secreted; c) detecting the surface-displayed POI by contacting the cells with a detection molecule, which binds the POI; and d) isolating cells based on the detection molecule.
    Type: Application
    Filed: May 15, 2006
    Publication date: October 19, 2006
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: James Fandl, Neil Stahl, Gang Chen, George Yancopoulos
  • Publication number: 20060148705
    Abstract: Nucleic acid molecules encoding fusion proteins which bind and inhibit vascular endothelial growth factor (VEGF). The VEGF-binding fusion proteins are therapeutically useful for treating VEGF-associated conditions and diseases, and are specifically designed for local administration to specific organs, tissues, and/or cells.
    Type: Application
    Filed: February 2, 2006
    Publication date: July 6, 2006
    Inventors: Thomas Daly, James Fandl, Nicholas Papadopoulos
  • Publication number: 20060107341
    Abstract: Compositions and methods for the inducible expression of genes in eukaryotic cells. Expression of a nucleotide sequence of interest is controlled by a regulatory fusion protein that consists of a transcription blocking domain and a ligand-binding domain. When the cognate ligand for the ligand-binding domain is present, transcription of the nucleotide sequence of interest is blocked. Upon removal of the cognate ligand, the nucleotide sequence of interest is transcribed. The method is useful for large scale production of a desired product in eukaryotic cells.
    Type: Application
    Filed: January 13, 2006
    Publication date: May 18, 2006
    Inventor: James Fandl
  • Publication number: 20060030529
    Abstract: Modified chimeric polypeptides with improved pharmacokinetics and improved tissue penetration are disclosed useful for treating eye disorders, including age-related macular degeneration and diabetic retinopathy.
    Type: Application
    Filed: September 1, 2005
    Publication date: February 9, 2006
    Inventors: Stanley Wiegand, Nicholas Papadopoulos, George Yancopoulos, James Fandl, Thomas Daly
  • Publication number: 20050260203
    Abstract: Modified chimeric polypeptides with improved pharmacokinetics and improved tissue penetration are disclosed useful for treating eye disorders, including age-related macular degeneration and diabetic retinopathy.
    Type: Application
    Filed: March 25, 2005
    Publication date: November 24, 2005
    Inventors: Stanley Wiegand, Nicholas Papadopoulos, George Yancopoulos, James Fandl, Thomas Daly
  • Publication number: 20050186623
    Abstract: A method for identifying and isolating cells which produce secreted proteins. This method is based upon a specific characteristic or the expression level of the secreted protein by transiently capturing the secreted protein on the surface of an individual cell, allowing selection of rare cell clones from a heterogeneous population. Also provided is the use of this method to generate cells which produce a desired level of secreted protein or secreted protein of a particular characteristic(s), and organisms which possess such cells. In particular, the method allows rapid isolation of high expression recombinant antibody-producing cell lines, or may be applied directly to rapid isolation of specific hybridomas, or to the isolation of antibody-producing transgenic animals. This method is applicable for any cell which secretes protein.
    Type: Application
    Filed: April 5, 2005
    Publication date: August 25, 2005
    Inventors: James Fandl, Neil Stahl, Gang Chen, George Yancopoulos
  • Publication number: 20050158829
    Abstract: A fusion polypeptide comprising (A)x—M—(A?)y, wherein A and A? are each polypeptides capable of binding a target receptor. The fusion polypeptides of the invention form multimeric proteins which activate the target receptor. A and A? may be each be an antibody or fragment derived from an antibody specific for a target receptor, such as the same or different ScFv fragmetns, and/or a ligand or ligand fragment or derivative capable of binding the target protein, M is a multimerizing component, and X and Y are independently a number between 1-10.
    Type: Application
    Filed: January 14, 2005
    Publication date: July 21, 2005
    Inventors: James Fandl, Gang Chen, Nicholas Papadopoulos, Thomas Aldrich
  • Publication number: 20050043236
    Abstract: Nucleic acid molecules and multimeric proteins capable of binding vascular endothelial growth factor (VEGF). VEGF traps are disclosed which are therapeutically useful for treating VEGF-associated conditions and diseases, and are specifically designed for local administration to specific organs, tissues, and/or cells.
    Type: Application
    Filed: June 29, 2004
    Publication date: February 24, 2005
    Inventors: Thomas Daly, James Fandl, Nicholas Papadopoulos